- Adjusted EPS: Catalent reported 65 cents per share, a significant increase from 9 cents per share year-over-year (y/y), and exceeding the estimate of 47 cents per share.
- Net Revenue: The company achieved net revenue of $1.30 billion, a 22% increase y/y, surpassing the estimate of $1.21 billion.
- Biologics Net Revenue: Biologics segment generated $605 million, up by 49% y/y, which was higher than the estimated $488.4 million.
- Adjusted EBITDA: Adjusted EBITDA increased to $305 million from $139 million y/y, beating the estimate of $253.2 million.
- Biologics EBITDA: The Biologics segment reported an EBITDA of $136 million compared to a loss of $12 million y/y, surpassing the estimate of $88.1 million.
- Pharmaceuticals & Consumer Health Net Revenue: This segment achieved $697 million, marking a 5.3% increase y/y, although slightly below the estimate of $704.4 million.
- Pharmaceuticals & Consumer Health EBITDA: The segment’s EBITDA rose to $217 million, a 16% increase y/y, higher than the estimate of $199.2 million.
- Analyst Recommendations: Catalent has 1 buy rating, 10 hold ratings, and 1 sell rating.
Catalent Inc on Smartkarma
Analysts on Smartkarma, like Baptista Research, are closely monitoring Catalent Inc, a key player in drug development and delivery technologies. In their report titled “Catalent Inc.: Gene Therapy Advancements Indicate A Bright Future Ahead? – Major Drivers,” Baptista Research highlights Catalent’s resilient performance in the face of market challenges. Despite facing headwinds, Catalent has maintained its full-year guidance through effective operations and strategic reviews. The analysts at Baptista Research are delving into the factors influencing Catalent’s stock price in the coming days, aiming to provide an independent valuation using a Discounted Cash Flow (DCF) methodology.
A look at Catalent Inc Smart Scores
| Factor | Score | Magnitude |
|---|---|---|
| Value | 3 | |
| Dividend | 1 | |
| Growth | 2 | |
| Resilience | 2 | |
| Momentum | 4 | |
| OVERALL SMART SCORE | 2.4 |
Smart Score is a compound score for the Company indicating its overall outlook. It is derived by taking an equally weighted average of underlying Factor scores computed by Smartkarma
With a mixed bag of Smart Scores, Catalent Inc‘s long-term outlook appears to have both strengths and weaknesses. While the company shows strong momentum, indicating positive price trends, its value score sits in the middle of the range. Catalent Inc‘s growth and resilience scores are also moderate, suggesting room for improvement in expanding operations and withstanding market turbulence. However, the low dividend score may be a concern for investors seeking consistent income from their holdings.
Catalent, Inc. stands as a provider of crucial delivery technologies and development solutions for a wide range of pharmaceutical products. Focusing on oral, injectable, and respiratory delivery technologies, Catalent addresses the needs of both small and large molecule biologics, as well as consumer health products. As investors weigh the Smart Scores, they may consider the company’s position in the pharmaceutical industry and its ability to adapt to evolving market demands.
Disclaimer: This article by Smartkarma is general in nature and based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. Note that our articles may not factor in the latest price-sensitive company announcements or qualitative material.
While all reasonable care has been taken in the preparation, Smartkarma makes no assurance about the accuracy of any generated data or content. All content is indicative only and should be independently checked for accuracy and confirmed before use. Smartkarma accepts no responsibility for any loss or damage caused as a result of any inaccuracy or error within the Lab online tools or generated data.
Have feedback on this article? Concerned about the content? Get in touch with us directly.
💡 Before it’s here, it’s on Smartkarma
Sign Up for Free
The Smartkarma Preview Pass is your entry to the Independent Investment Research Network
- ✓ Unlimited Research Summaries
- ✓ Personalised Alerts
- ✓ Custom Watchlists
- ✓ Company Analytics and News
- ✓ Events & Webinars
